{"id":"W4310566600","doi":"10.1001/jamaoncol.2022.5610","title":"Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Aptitude Health; Eisai; National Breast Cancer Foundation; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; Puma Biotechnology; Medac; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; BioMarin Pharmaceutical; Mylan; Ionis Pharmaceuticals; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Vertex Pharmaceuticals; Foundation Medicine; Genomic Health; Breast Cancer Research Foundation; Jounce Therapeutics; Celgene; Genentech; Veracyte; Amgen; Radius Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Yale University; Sanofi; GlaxoSmithKline; Carrick Therapeutics; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Placebo; Oncology; Breast cancer; Pertuzumab; Cancer; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00131302,0.001071054,0.002613399,0.0005335939,0.0003280519,0.0009717831,0.0006088634,0.001408877,0.005626569],"category_scores_gemma":[0.001830422,0.0004622247,0.001780611,0.0004692341,0.000832545,0.001100095,0.0003554019,0.001996304,0.0006621096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006126101,"about_ca_system_score_gemma":0.0008544847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005538366,"about_ca_topic_score_gemma":0.001620221,"domain_scores_codex":[0.9993576,0.0003098424,0.00007120846,0.0001100344,0.00003966565,0.0001116162],"domain_scores_gemma":[0.9991313,0.0002917627,0.000228224,0.00004639235,0.00003873067,0.0002636782],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9782822,0.003829442,0.0003925369,0.0003778437,0.0004851429,0.00002396299,0.0000223352,0.0001871517,0.001888646,0.00006329366,0.0003434938,0.014104],"study_design_scores_gemma":[0.7791267,0.2144474,0.002923581,0.00005381844,0.0009479325,0.00004676509,0.00002930459,0.000617745,0.0008268282,0.0001922556,0.0007695517,0.00001821161],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854327,0.008392772,0.0002861531,0.0005602953,0.0008396442,0.001682261,0.000570728,0.00007207055,0.00216343],"genre_scores_gemma":[0.9936368,0.002331263,0.0003794047,0.0003577547,0.0004350946,0.001246859,0.0003310186,0.000006138381,0.001275557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005626569,"threshold_uncertainty_score":0.01882273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009678729924896167,"score_gpt":0.2817659237388417,"score_spread":0.2720871938139456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}